Factsheet
May 29, 2018

Immune Landscape Signatures for Characterization of Tumor Microenvironment and Response to Therapy

Gene expression and analysis for detection of 11 Immune Landscape Signatures
As part of a broad immuno-oncology assay portfolio, Q2 Solutions| EA Genomics offers gene expression and analysis services for the detection of Immune Landscape Signatures attributable to 11 key immune cell subtypes, individual genes, and ratios.

Results for the individual signatures are output as Immune Landscape Signature Scores, non-standardized and standardized across the project and can be used to determine immunogenic status of solid tumors. These signatures can also be used in a single-or multi-factor analysis of treatment response and survival, along with other clinicopathological and genomic co-factors such as tumor mutational burden.

Download factsheet to learn more about product highlights and deliverables.

Related Services:
Tumor Mutational Burden (TMB) Assay for Response to Immunotherapy

TMB assay utilizing whole exome sequencing (WES) methodology and proprietary variant analysis compendium

Q2 Solutions Biomarker Services

Providing tools and experience to maximize your biomarker strategy

Q2 Solutions Genomic Laboratory Services

Genomic Know-How® for your drug development needs

The importance of bioinformatics in immuno-oncology development

Big data solutions and bioinformatics services for genomic insights

Read More